<DOC>
	<DOCNO>NCT02764671</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety 10μg/0.5ml Recombinant Hepatitis B Vaccines ( Saccharomyces Cerevisiae ) Healthy Neonates .</brief_summary>
	<brief_title>Safety Immunogenicity Recombinant Hepatitis B Vaccines Neonates</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects healthy fullterm infant birth , Apgar score ≥8 ; Subjects birth weight ≥ 2500g ; Subjects ' guardian able understand sign inform consent ; Subjects comply requirement protocol . Family history eclampsia , epilepsy encephalopathy ; Subjects ' birth mother immune system dysfunction , history organ transplantation blood dialysis ; Subjects ' parent medical history allergic ingredient vaccine , include supplementary material formaldehyde ; Subjects ' parent medical history allergic combine hepatitis A B vaccine ( HAB ) hepatitis B vaccine ; Subjects serious acute chronic disease ; temperature ≧37.1℃ ; Any condition opinion investigator , may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>recombinant hepatitis B vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>